FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Bayer NDA Accepted for Next-Gen Contrast Agent

FDA accepts Bayers NDA for gadoquatrane, a next-generation gadolinium-based contrast agent for use in magnetic resonance imaging.

Biologics

Sen. Cassidy Seeks Postponement of Vaccine Panel

In the wake of CDC director Susan Monarezs firing, Senate HELP Committee chair Bill Cassidy (R-LA) calls on HHS to postpone a just-announced Advisory ...

latest-news-card-1
Human Drugs

FDA Recommends More Leqembi MRIs

FDA says it is requiring a change in labeling for Eisai/Biogens Alzheimers drug Leqembi to call for an earlier MRI monitoring scan to identify patient...

latest-news-card-1
Human Drugs

FDA-483 on IntegraDose Inspection

FDA releases the form FDA-483 with six observations from an inspection at the Minneapolis, MN-based IntegraDose Compounding Services outsourcing facil...

latest-news-card-1
Medical Devices

Integra Recalls Surgical Applicators Over Sterility Issues

Integra LifeSciences recalls (Class 1) its Extended Tip Applicators due to sterility concerns.

latest-news-card-1
Human Drugs

Platinum Biologics Selling Unapproved New Drugs: FDA

FDA warns Orlando, FL-based Platinum Biologics that it is illegally marketing unapproved new drugs.

latest-news-card-1
Human Drugs

Hikma Injectables FDA-483 Out

FDA releases the form FDA-483 with four observations from an inspection at the Dayton, NJ-based Hikma Injectables USA outsourcing facility.

latest-news-card-1
Human Drugs

Researchers Affirm Mifepristone Safety to FDA

More than 260 reproductive health researchers urge FDA to continue to support mifepristone based on its 25-year record of safety and effectiveness in ...

latest-news-card-1
Human Drugs

FDA Looking at MASH Surrogate

FDA says it has accepted an Echosens Letter of Intent to develop Liver Stiffness Measurement by Vibration-Controlled Transient Elastography as a surro...

latest-news-card-1
Human Drugs

Grace Therapeutics NDA for Hemorrhage Drug Submitted

FDA accepts for review a Grace Therapeutics NDA for GTx-104 (nimodipine for injection) for treating patients with aneurysmal subarachnoid hemorrhage.